Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes by unknown
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IgA isthe majorIgisotypein mucosalsecretions andconstitutesthe great majority
ofthe Ig synthesized in mucosal tissues (1, 2). In contrast, IgA is a minor fraction
ofboth the total serum Ig and the response by spleen and lymph node cellsto most
antigens (3). The physiological basisfor thisdifferential expression ofIgAin various
lymphoid tissues is not yet understood. A number ofcytokines have been reported
to preferentially enhance IgA production in vitro, including IL-5 (4-7), IL-2 (4),
and IL-4 (8). In all cases, however, these factors cause a <10-fold increase in IgA
relative to total Igproduction, and none have yet been shown to be present at rela-
tively high concentrations in mucosal tissues.
We have reported the cloningofacDNA encoding murine IL-5 using as an assay
the ability ofIL-5 to enhance IgA production in cultures ofLPS-stimulated B cells
(7). The cloningstrategy involved transienttransfection ofmonkeyCOS7 cellswith
pools ofcDNA clones from a T cell cDNA library, followed by assaying ofthe trans-
fected cell supernatants fortheir IgA-enhancing activity. Since COS7 cells produced
TGF0, and TGFa hadbeenshown to inhibithuman Bcell responses (9), we exam-
ined the effects ofTGF13 on the expression ofindividual Ig isotypes in cultures of
LPS-stimulated B cells. These experiments led to the unexpected observation, de-
scribed herein, that TGF0 substantially enhances IgA production, yet inhibits the
production of most other Ig isotypes.







Female BALB/c ByJ micewereobtained from The Institute forMedical Research,
SanJose, CA. Mice were used at 8-16 wk of age.
Cytokines.
￿
Porcine TGFS1 was obtained from R &D Systems, Minneapolis, MN. Mu-
rine IL-5 waspurified from supernatantsofthe T cell clone MB2-1 by the method ofBond
et al. (5). Murine rIL-2 was expressed in Escherichia coli and purified to >95°Io purity by
Schering Research, Bloomfield, NJ. The specific activity ofthe IL-2 was 1.25 x 108 U/mg,
where 1 U/ml supports one-half maximal growth of the T cell line HT2.
In Vitro Cultures andAssays.
￿
The basic in vitro culture system (10) and the purification
of surface IgA' (sIgA') and sIgA- Peyer's patch (PP) populations (11) have been described
previously. Unless otherwise indicated, T cell-depleted populations were stimulated for 1 d
with 8 Rg/ml Salmonella typhosa LPS at 106 cells/ml. The cells were then diluted twofold
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inmediumcontaining thecytokine(s) tobetested andculturedforan additional 6 d in0.2-ml
round-bottomed microtiterplates. Supernatants wereharvested at theendofthecultureperiod
and frozen until assayed. Each "culture" represents a pool ofeight microtiter wells and all
cultures were performedinduplicate ortriplicate. TheSDofthe Iglevels in replicate cultures
was <25% of the mean in most experiments. Isotype-specific ELISAs were performed on
theculturesupernatantswithmethodsand reagents that havebeen describedpreviously (10).
Results
TGF--,CI Enhances theProduction ofIgA.
￿
TGF-0 hasbeen reported tobe apotent inhib-
itorofboth proliferation and Igproductionby Staphylococcusaureus-activated human
B cells (9). A similar inhibitory effect by TGFa on proliferation (Lebman, D. A.,
F D. Lee, and R. L. Coffman, manuscript in preparation) and Ig production (Fig.
1) was observed in cultures of LPS-stimulated mouse B cells. However, analysis of
thelevels ofindividual Igisotypes in cultures containing TGFa gave an unexpected
result. At concentrations of TGF0 that caused a N10-fold decrease in IgM, IgGl,
IgG3, andtotalIgproduction, the productionofIgA was increased 10-20-fold(Fig.
1). Four different lots of porcine TGFX31 stimulated maximum IgA production at
aconcentration of2 ng/ml, and this concentrationwasused in subsequent experiments.
IL-2 andIL-5, in Combination with TGF--,B, FurtherEnhanceIgA Production.
￿
Twoother
cytokines have been reported to enhance IgA levels in LPS-stimulated cultures in
an isotye-specific manner, IL-2 (4) and IL-5 (4-7). We therefore tested combina-
tions ofthese factors and TGF(3 fortheireffects on the expression of IgA and other
isotypes. The effects on six Ig isotypes ofTGF0, alone or in combination with IL-2
or IL-5, are shown in Table I. The results are typical of three such experiments.
Supernatant IgA levels were increased as much as 40-50-fold in culturescontaining
TGF-0 and IL-2, and IgA increased from -0.1% to 15-25% oftotal Ig produced
(Table I). There appears to besynergybetween the actions ofthese twofactors, since
the IgA level, induced by a combination ofTGF-0 and IL-2, was, in this example,
nine times the sum ofthe IgA levels induced bythetwofactors separately. IL-5 also
enhanced the TGFS-induced IgA response, but to a lesser extent than IL-2. All
cytokineswere used atthe optimumconcentrations, asdetermined indosetitrations
(data not shown). TGF(3 caused substantial inhibition ofthe three major isotypes
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Titration of TGF-0 into cultures of LPS-
stimulated, T cell-depleted spleen cells. Data foreach iso-
type are expressed as the percent of the control response,
i.e., theresponse obtained with no addition ofTGF-S. This







Effect of TGF,B, IL-5, and IL-2 on Levels of Individual Ig Isotypes
" TGF-0 was used at 2 ng/ml, IL-5 at 1 ng/ml, and IL-2 at 10 ng/ml.
in these cultures, IgM, IgG1, and IgG3, and some inhibition of the small IgG2a
response. IgG2b levels were relatively unaffected by TGFa and, in some experi-
ments, were enhanced two- tothreefold. The addition ofIL-2 or IL-5partly reversed
the suppression of total Ig production, in addition to further stimulating IgA
production.
TGF-,B Stimulates IgA Production from Surface IgA- B Cells.
￿
Two principal mecha-
nisms could explain the preferential enhancementofIgA relative to totalIg produc-
tion by TGF0. TGF0 could either cause an increase in the frequency with which
Bcells switch toIgA production, orpreferentially stimulatethe growth and/or differen-
tiation ofcells that switched to IgA independently ofTGF0. To distinguish which
ofthese mechanisms might be responsible for the increase in IgA, PP B cells were
separated by the FAGS into sIgA- and s1gA' subpopulations, then cultured with
TABLE II
TGF-,B Enhances IgA Secretion by sIgA- PP Cells
in LPS-stimulated Cultures
Upon reanalysis, the sIgA- population contained <0.5% sIgA' cells and the
sIgA' population contained 6.6% sIgA- cells.
" TGF-l3 was used at 2 ng/ml and IL-2 at 10 ng/ml.
LPS-stimulated
T-depleted spleen cells+ IgA IgG2A
Supernatant levels




Medium 85 40 381 1,220 4,532 63,900 0.12
TGF-S. 866 20 450 223 695 7,800 8.6
IL-5 380 45 814 2,000 4,870 115,000 0.13
TGF-0 + IL-5 2,380 18 680 210 773 14,800 13
IL-2 303 290 990 3,200 4,000 103,000 0.27
TGF-0 + IL-2 6,570 14 673 400 1,094 23,200 21
B cell source Additions IgA
ng/ml
Total PP Medium 198
TGF-S. 1,100
IL-2 150
TGF-l3 + IL-2 2,650
Total PP, stained, not sorted Medium 54
TGF-li + IL-2 790
sIgA- PP Medium 21
TGF-/3 172
IL-2 34
TGF-0 + IL-2 577
sIgA' PP Medium 485
TGF-l3 67
IL-2 500





LPS, TGF/3, and/or IL-2. Since 5-8% ofthe B cells in PP were sIgA+, the effects
ofTGFf3 and IL-2 on both sIgA+ and sIgA- subpopulations could be measured.
Preliminary experiments had shown that PP and spleen cells respond similarly to
TGFf3 or TGF(3 plus IL-2 (data not shown).
TGF(3 enhanced IgA production by the sIgA- population, and this was further
augmented bytheaddition ofIL-2 (Table II). This increase in IgA production does
not appear to come from contaminating s1gA+ cells, since TGF0 inhibited IgA
production by sIgA+ cells. However, the response ofthe sIgA+ population may not
fully reflect their contribution to the response ofunfractionated PP cells, since the
treatment with anti-IgA antibodies consistently causes a two- to three-fold inhibi-
tion of the IgA response. A large increase in IgA production is likewise induced
by TGF0 in splenic sIgA- B cells and, in this case, staining ofthe unfractionated
population with anti-IgA doesnot inhibit subsequent IgA production (Lebman, D. A.,
F. D. Lee, and R. L. Coffman, manuscript in preparation).
Discussion
The cytokine TGFS proved to be a potent inhibitor of Ig production by LPS-
stimulated murine B cells (Table I). Despite this, TGF/3 induced a N10-20-fold ab-
solute enhancement ofIgA production. TheIgA responsecould befurtherenhanced
bythe addition ofeither IL-2 orIL-5, although IL-2wasmoreeffective. Either cytokine
caused a partial reversal of the inhibitory effects ofTGFf3 on most other isotypes.
The net result was that cultures containing optimum concentrations ofTGF0 and
IL-2 produced 50-100 times as much IgA and only two- to threefold less total Ig
than control cultures. Thus, IgA represented 15-25% of total Ig in cultures con-
taining TGF(3 and IL-2, compared with 0.1-0.27o of total Ig in cultures with no
added cytokines.
A number of other cytokines and growth factors have been examined in LPS-
stimulated B cell cultures, including IL-2 through IL-6, granulocyte-macrophage
CSF, IFN-,y, TGFa, epidermal growth factor, basic fibroblast growth factor, and
insulin-like growth factor (4, and unpublished results). Only IL-5 and IL-2 cause
significant specific stimulation of IgA, and these effects are small compared with
thosecaused byTGF0. TGF0inducesessentiallythesame responses in highly purified
B cell populations and in the T cell-depleted spleen cell populations used in most
ofthese experiments (data not shown), suggesting that both the IgA enhancement
and the suppression oftotal Igproduction reflectdirect actions ofTGFf3 on B cells.
An important question about the mechanism ofIgA enhancement by TGF/3 is
whetherit affectsthe probabilitythat Bcells will switch to IgAorwhether it specifically
amplifiesthe response ofB cellsthat have switched to IgA independently ofTGFf3.
This question was addressed by testing the response of sIgA- and sIgA+ PP B cells
to TGFf3 or TGF/3 + IL-2. Either addition caused alarge increase in IgA produc-
tion by sIgA- B cells, suggesting that TGF0 enhances the switch to IgA produc-
tion. Supporting evidence comes fromexperiments that demonstrated that TGFf3-
enhanced IgA production comes from splenic B cells that are sIgA- at the start of
culture, but express readilydetectable sIgA after4 d ofculture. Furthermore, TGF
f3 induced sterile mRNA transcripts from unrearranged Ca loci before the appear-
ance ofdetectable sIgA+ cells or secreted IgA (Lebman, D. A., F. D. Lee, and R. L.





TGF0 was originally described as a factor that caused anchorage-independent
growth of fibroblasts (12). It is active on many cell types and can either stimulate
or inhibitcellular proliferation anddifferentiation, depending on thecell type (reviewed
in reference 13). It is produced by awide varietyofcell types (14), including platelets
(12), activated B cells (9) and T cells (15), and macrophages (16). In general, TGF0
is quite inhibitory for lymphocytes, having been shown to inhibit proliferation and
differentiation of B cells (9, 17) and T cells (15, 18, 19).
These experiments clearly show that polyclonally activated spleen and PP B cell
populations, under certain conditions, can be induced to secrete IgA representing
up to 25% of total Ig secretion. In principle, this type of response could account
for the large number of sIgA+ B cells and the predominance of IgA secretion ob-
served in gut-associated lymphoid tissues. The experiments reported here, however,
provide no direct evidence that TGFf actually plays a role in the development of
IgA responsesin mucosal tissue. Little information is availableaboutTGF0expres-
sion in gut-associated lymphoid tissues, although activated macrophages and lym-
phocytes secreting TGF/3 should be present at thesites ofongoing mucosal immune
responses.
Summary
The addition of TGF# to cultures of LPS-stimulated murine B cellscauses a -10-
fold enhancement ofIgA production, yet causes a 10-folddecrease in total Ig produc-
tion. IL-2 and, to a lesser extent, IL-5 synergize with TGFa to further enhance
IgA production and partially reverse the inhibition oftotal Ig production. IgA con-
situtes only N0.1°Jo of total Ig in LPS-stimulated cultures, but that percentage rises
to 15-25% in cultures to which TGF/3 and IL-2 are added. TGF0 induces a sub-
stantial increase in IgA production from sIgA- B cells but inhibits IgA production
by sIgA+ cells. This finding suggests that TGF(3 acts as an isotype-specific switch
factor for IgA.
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